A new drug has shown promise in combating Parkinson’s disease while minimizing unwanted side effects.

Levodopa — which is converted into dopamine in the brain and targets the D2/D3/D4 dopamine receptors — has been linked to side effects including sleep disorders, hallucinations, impulse ...

won't undermine its bid to extend the uses of the fast-growing dopamine D2/D3 receptor partial agonist, one of the star assets to emerge from its $63 billion mega-merger with Allergan. In its ...

The dopamine D2/D3 receptor partial agonist has proved to be one of the star assets to emerge from AbbVie's $63 billion mega-merger with Allergan which closed in 2020. Already established as an ...